BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities
BioCardia announces its focus for 2026 on submitting CardiAMP Cell Therapy for ischemic heart failure approval to Japan's PMDA, aiming for initial approval for a 20,000-patient subgroup. The company highlights its clinical trial enrollment progress in the US, innovative delivery platform partnerships, and plans for strategic collaborations around i…